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On the morning of July 22, 2011, many friends and admirers of 
Chief Judge Rader gathered at the University of Washington’s 
High Technology Protection Summit to focus on the Chief Judge’s 
many important opinions written during his more than 20 years on 
the Court of Appeals for the Federal Circuit. The morning 
consisted of two lengthy sessions following a keynote speech by a 
former student of mine, now a very experienced patent judge, the 
Honorable Marilyn L. Huff. The morning concluded with an 
address by the President of the University of Washington, Michael 
K. Young. Because President Young was instrumental in making 
the Chief Judge a permanent member of The George Washington 
University Law School faculty, his talk was the perfect capstone to 
the morning’s events. Much of the afternoon was focused on Chief 
Judge Rader’s influence on the patent laws of countries other than 
the United States. 
Many of the speakers were kind enough to prepare formal 
remarks for the conference, and these papers form the basis for this 
festschrift. They include two excellent papers on the Chief Judge’s 
influence on foreign patents law, one by Esther H. Lim, a former 
law clerk to Chief Judge Rader, dealing with Chinese patent law. 
The second, by Kaoru Kuroda and Eiji Katayama, discusses an 
important aspect of Japanese patent law. In addition, the papers 
include an article by Professor Robert W. Gomulkiewicz 
approving of the reasoning of an important contract law opinion 
written by the Chief Judge. However, I will focus this introduction 
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on the papers that deal with the role of the Chief Judge in the 
development of American patent law doctrine. 
I turn first to Professor Peter Lee’s analysis of what he calls 
“Antiformalism.” He finds evidence of Antiformalism in various 
decisions of the Chief Judge, but I suspect the record is more 
complicated because the Chief Judge believes in giving sound 
guidance to the public by means of easily understood rules so as to 
minimize legal costs. For example, is his opposition to the Federal 
Circuit’s written description requirement for originally filed claims 
an example of Antiformalism or simply a questioning of why a 
new, vague, and unneeded requirement was added for originally 
filed claims? I believe it is the latter. Indeed, I do not believe any 
opinion of the Federal Circuit has answered his critique of using 
written description for originally filed claim as an added 
requirement alongside enablement. 
Another general topic is the one treated by Judge Huff: the 
appropriate use of experts in patent cases. This is an area that the 
Chief Judge has covered extensively in a number of opinions 
including those written while sitting as a trial judge by designation. 
It fits in with his intense interest in claim construction and damage 
law. Judge Huff’s article also gives the reader an inside view of 
how the jurisprudence of the Chief Judge has impacted the patent 
trial work of a distinguished district judge with a heavy patent 
docket. 
Turning now to obviousness, the article by Professor Mark D. 
Janis is instructive in showing how obviousness considerations 
have impacted the Federal Circuit’s utility and written description 
jurisprudence. The Chief Judge realized many years ago that In re 
Deuel1 was wrongly decided and needed to be overturned. He said 
as much in his dissent in In re Fisher,2
                                                                                                         
1 51 F.3d 1552 (Fed. Cir. 1995).  
 where he had the better 
argument, but politically the other panel members had no choice 
but to use the utility doctrine to invalidate the plainly obvious 
claims before the court. In addition, Professor Janis believes that 
the Federal Circuit has developed the written description doctrine 
for originally filed claims as another counterweight to In re Deuel. 
2 421 F.3d 1365 (Fed. Cir. 2005). 
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This is probably the case, although one that is hard to prove. In any 
event, it was the Chief Judge himself who finally laid In re Deuel 
to rest by invoking KSR3 in In re Kubin.4
Professor Janis also reviews In re Translogic,
 
5 where the Chief 
Judge explained that any prior art reference and its obvious 
variations invalidates a claim that reads on any of its obvious 
variations. He carefully explained that this was the original error 
made by the Federal Circuit in KSR. However, the Chief Judge’s 
role in Dystar Textilfarben GmbH v. C.H. Patrick Co.,6
Turning now to Professor Katherine White’s review of a 
number of the Chief Judge’s infringement decisions, I want to 
comment specifically on his concurring opinion in Johnson & 
Johnston.
 which 
issued shortly before the oral argument in KSR, was also extremely 
important in the modern development of obviousness 
jurisprudence. Dystar served as a vehicle for the Federal Circuit to 
explain to the Supreme Court how it should interpret both its own 
precedents and those of the Federal Circuit. The opinion was 
drafted by then-Chief Judge Paul Redmond Michel, with only 
Chief Judge Rader joining in the opinion. In explaining both lines 
of cases, Dystar made them look as good as possible. In essence, 
this was an amicus brief by Judges Michel and Rader that was 
carefully and wisely followed by Justice Kennedy. Indeed, while 
the Supreme Court is not a court that corrects errors, but rather 
deals with policy, after reading Dystar Justice Kennedy essentially 
left the policy set forth in its interpretation or rendition of the 
relevant case law alone and proceeded to fix the error made by the 
unpublished opinion in KSR. This may have saved the patent 
system from a train wreck. 
7
                                                                                                         
3 KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007). 
 I believe this is the best-reasoned opinion ever written 
anywhere in the world on the doctrine of equivalents. It actually 
explains when a sound patent system should permit non-textual 
infringement. Moreover, it was issued on March 28, 2002, and the 
4 561 F.3d 1351 (Fed. Cir. 2009). 
5 In re Translogic Tech., Inc., 504 F.3d 1249 (Fed. Cir. 2007). 
6 464 F.3d 1356 (Fed. Cir. 2006).  
7 Johnson & Johnston Assoc. v. R.E. Service Co., Inc., 285 F.3d 1046 (Fed. 
Cir. 2002). 
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Supreme Court decided Festo Corp. v Shoketsu Kinzoku Kogyo 
Kabushiki Co.8 on May 28, 2002, precisely two months to the day 
later. Justice Kennedy’s opinion tracks the Chief Judge’s 
concurring opinion with respect to when a patentee may overcome 
a prosecution history estoppel except on one relatively small point. 
The Supreme Court would permit the use of the doctrine of 
equivalents with respect to a claim limitation even where an 
estoppel existed if adding the claim limitation was “tangential.” In 
addition, of course, the Supreme Court following its own 
precedents divided the doctrine of equivalents question into two 
categories. In one, there is a prosecution history estoppel. In the 
other, there is no estoppel. The concurring opinion would make no 
such distinction, a distinction which is makes little sense as I have 
explained elsewhere.9
I now turn to Professor John M. Golden’s paper on 
Therasense.
 In short, had it followed the Chief Judge 
fully, the Court would not have erred by adding “tangential” and 
would have eliminated the unwise distinction based on prosecution 
history estoppel. But at least the Court went part way toward 
developing as the Chief Judge explained a sound doctrine of 
equivalents. 
10 Although mentioned in his sixth footnote, Professor 
Golden might have made more of the powerful dissent of the Chief 
Judge in Aventis Pharma S.A. v. Amphastar Pharmaceuticals, 
Inc.11
                                                                                                         
8 535 U.S. 722 (2002). 
 That important case committed one of the great injustices of 
modern patent litigation. It involved a claim that a leading French 
scientist, Dr. Andre Uzan, intentionally and with the intent to 
deceive failed to disclose the dosage (60 mg) used to test the half-
life of a prior art product when he compared it to the half-life of 
the claimed product, the very important drug Lovenox. Because 
ordinarily at pharmaceutically relevant doses first order chemical 
kinetics dictate that the half-life is independent of dosage, it is 
9 Martin J. Adelman, Patent Claiming in the United States: Central, 
Peripheral, or Mongrel?, 1 IP THEORY 71 (May 8, 2012) 
http://www.repository.law.indiana.edu/ipt/vol1/iss2/2. 
10 Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 
2011) (en banc). 
11 525 F.3d 1334 (Fed. Cir. 2008). 
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surely understandable that a leading scientist familiar with the art 
would not believe it important to reference the dosage when 
comparing the measured half-life of a pharmaceutical product at 
least at ordinary dosages. Just ask any doctor whether he or she 
believes there is a significant difference in half-life for any drugs 
used by the doctor at pharmaceutically relevant dosages. 
Unfortunately, even though anyone with access to the Internet 
could learn about first-order kinetics, the dispute turned on 
measuring the half-life of Lovenox at different disclosed dosages 
and then measuring the half-life of a prior art composition at an 
undisclosed relatively high dosage for the purpose of showing that 
the half-life of Lovenox was greater than the half-life of the prior 
art formulation. From the prospective of the patent applicant, the 
lower the half-life of the prior art composition the better the test 
would look with respect to patentability. Since the withheld dose 
was on the high side, it was either irrelevant, the most likely 
situation, or it made the test appear slightly worse for the purposes 
of patentability as at some point increasing the dosage overloads 
the body and therefore causes a departure from first order kinetics, 
thereby increasing the measured half-life. However, given the 
variability of tests for half-life, some internal company data 
showed that the half-life at 40 mg when measured was greater than 
at 60 mg for the prior art product. A knowledgeable scientist would 
know that this result was most likely the result of experimental 
variation and not an underlying characteristic of the products and 
hence would not believe that the prior art dosage level was 
important.  
In any event, the Chief Judge sensed that there was no reason 
for Dr. Uzan to deceive the USPTO and risk besmirching his 
distinguished reputation. As a result, he wrote a powerful opinion 
on intent. Of course, he was correct as I am sure that Dr. Uzan is 
wondering what is the matter with the education of Americans that 
they do not know about first-order kinetics in chemistry or that 
half-life is usually constant over the range of pharmaceutical doses. 
While the Federal Circuit did not correct the manifest injustice of 
its Aventis Pharma opinion by going en banc and reversing, it did 
try and make amends in Star Scientific, Inc., v. R.J. Reynolds 
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Tobacco Co.12 and ultimately in Therasense. Unfortunately while a 
reading of the full opinion of the Board of Appeal in the European 
Patent Office discussing the prior art reference in Therasense 
shows that there was no conflict between the record in the USPTO 
and the proceedings in the USPTO, even after the en banc 
Therasense opinion, a true tour de force, Judge Alsup remained 
unmoved and found “inequitable conduct” under the new 
standards.13
In sum, this festschrift covers only a small slice, but an 
important one, of the extensive work that the Chief Judge has done 
in his judicial career to date. We hope there will be much more 
significant judicial work in the future from him. 
 Whether Therasense will make the hoped for 
correction of inequitable conduct law is for the future. The 
implications raised by Judge Alsup’s opinion on remand and the 
Federal Circuit’s recent decision in Aventis Pharma S.A. v. 
Hospira, Inc. are not encouraging, 
                                                                                                         
12 537 F.3d 1357 (Fed. Cir. 2008). 
13 Therasense, Inc. v. Becton, Dickinson & Co., No. C 04-02123 WHA, 
2012 WL 1038715 (N.D. Cal. Mar. 27, 2012). 
